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Abstract
Background: Due to frequent mutations in certain cancers, FGFR3 gene is considered as an oncogene. However, in
some normal tissues, FGFR3 can limit cell growth and promote cell differentiation. Thus, FGFR3 action appears
paradoxical.
Results: FGFR3 expression was forced in pancreatic cell lines. The receptor exerted dual effects: it suppressed tumor
growth in pancreatic epithelial-like cells and had oncogenic properties in pancreatic mesenchymal-like cells. Distinct
exclusive pathways were activated, STATs in epithelial-like cells and MAP Kinases in mesenchymal-like cells. Both
FGFR3 splice variants had similar effects and used the same intracellular signaling. In human pancreatic carcinoma
tissues, levels of FGFR3 dropped in tumors.
Conclusion: In tumors from epithelial origin, FGFR3 signal can limit tumor growth, explaining why the 4p16.3 locus
bearing FGFR3 is frequently lost and why activating mutations of FGFR3 in benign or low grade tumors of epithelial
origin are associated with good prognosis. The new hypothesis that FGFR3 can harbor both tumor suppressive and
oncogenic properties is crucial in the context of targeted therapies involving specific tyrosine kinase inhibitors
(TKIs). TKIs against FGFR3 might result in adverse effects if used in the wrong cell context.
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Introduction
The fibroblast growth factor receptor 3 (FGFR3) belongs to
the family of tyrosine kinase receptors [1]. FGFR activation
induces proliferation and migration in many physiological
situations, but in some cell types, FGF signaling induces
differentiation and/or cell proliferation inhibition and/or
cell death. Deregulation of FGF signaling in carcinogenesis
has been widely explored. On one hand, it is now well-
established that FGFs and FGFRs can be oncogenic
through different intracellular molecular targets leading to
increased cell proliferation, cell survival, angiogenesis and
promotion of cell migration and invasion. On the other
hand, FGF tumor suppressive effects are more and more
documented, in particular for FGFR2 signaling (reviewed
in [1]). In normal tissues, FGFR3 might have a negative
impact on cell growth, the most striking example being
its function during bone development confirmed by
activating mutations in human skeletal disorders. In
growth plates of the developing long bones, FGFR3
negatively controls cell proliferation and induces chondro-
cyte apoptosis in late embryonic stages (reviewed in [2]). In
the same way, mice lacking FGFR3 receptor showed
extended bone length [3] and transgenic mice with activat-
ing mutations are dwarfs [4]. In pancreatic and intestinal
mouse tissues, we previously showed that FGFR3 has a
negative impact on normal epithelial cell proliferation
[5,6]. In cancers, activating somatic mutations of FGFR3
were first characterized in bladder cancer and cervix cancer
[7]. In bladder cancers, mutations occur preferentially in
non-muscle invasive disease and much less commonly in
muscle-invasive lesions, suggesting that these alterations
could be linked to a favorable course of the disease in non
invasive papillary bladder cancer [8]. Seborrheic keratoses
and epidermal nevi, benign tumors of the skin, can also
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present activating mutations of FGFR3 (reviewed in [9]).
In colorectal tumors, mutations were possibly inactivating
mutations, while decreased expression of FGFR3 was
found in colorectal cancer cell lines [10,11] and tumors
[11]. Conversely, multiple myelomas can harbor a t(4:14)
intergenic translocation bringing FGFR3 gene under
the control of the strong immunoglobulin heavy chain
promoter, participating in tumor progression [12].
Despite contradictory results in different tumor types
and models, to date, FGFR3 pathway is considered to be
oncogenic in human tumors, by contrast to the situation
in normal development of the long bones. Moreover, little
is known on FGFR3 actions in pancreatic tumors. We
explored the actions of FGFR3 in modulating pancreatic
cancer cell behavior.
Results
FGFR3 overexpression has tumor suppressive effects
FGFR3 is expressed as two splice variants, the FGFR3-IIIb
and FGFR3-IIIc. Forced expression of either splice variants
was performed in two pancreatic ductal adenocarcinoma
(PDAC) cell lines: the Capan-2 and the BxPC-3 pancreatic
cells. The capacities of the cells to form clones in low
density cultures was increased by both FGFR3-IIIb and IIIc
as compared to the control condition, except for the IIIb
splice variant in the BxPC-3 cells (Table 1). Interestingly,
this effect was maintained when cells were transduced
with a FGFR3-IIIc cDNA lacking tyrosine kinase activity
(K508M mutation, FGFR3-IIIc-KD, Table 1). Interestingly
however, the areas of the colonies were smaller with
FGFR3 overexpression but not with FGFR3-IIIc-KD
(Table 1). Noticeably, clones overexpressing high levels of
FGFR3 appeared much smaller than clones expressing
lower levels as attested by ZsGreen protein fluorescence
intensity (Figure 1A, left panel). Mean fluorescence inten-
sities were lower for cells transduced with active forms of
FGFR3 (Figure 1A, right panel). Thus, FGFR3 promoted
colony formation of pancreatic cells, but clone expansion
was reduced. This latter effect depended on active FGFR3
tyrosine kinase. Furthermore, forced expression of both
FGFR3 splice variants in Capan-2 and BxPC-3 cells
reduced the cell proliferation (Figure 1B). Flow cytometry
analyses did not evidence major differences in the distri-
butions of cells in the cell cycles phases (Additional file 1:
Figure S1), but a significant and important accumulation
of cells in sub-G1 was observed, suggesting that FGFR3
induced apoptosis (Additional file 1: Figure S1 and
Figure 1C).
Over time Capan-2 cells that appeared viable were still
detectable by light microscopy. Viable cells stopping
proliferation, but not proceeding to apoptosis, could be
undergoing senescence. Acidic beta-galactosidase staining
associated with the senescent phenotype in numerous
studies (reviewed in [13]). It was significantly increased in
FGFR3-IIIb and -IIIc overexpressing cells compared with
the controls (Table 1, and Additional file 2: Figure S2A) in
Capan-2 cells, but not in BxPC-3 cells where senescence
did not seem to occur at all.
To further test whether the effects of FGFR3 seen in vitro
were valid in vivo, transduced cells, sorted by flow cytome-
try were xenografted in immune-compromised mice
and tumor progression was examined. Very interestingly,
overexpression of both FGFR3-IIIb and –IIIc inhibited
Capan-2 and BxPC-3 tumor growth (about 2-fold de-
crease, Table 1). Noticeably, establishment of single clones
overexpressing FGFR3-IIIc in Capan-2 cells showed
that tumor growth inhibition was dependent on FGFR3-
IIIc expression levels (R2 about 0.87, Additional file 3:
Figure S3). The tumor masses were not different from
controls when Capan-2 cells overexpressed FGFR3-IIIc-KD,
suggesting that the negative impact on tumor progression
depended on FGFR3 tyrosine kinase activity (Table 1).
FGFR3 impacts pancreatic epithelial- and mesenchymal-like
cells differently
FGFR3 behaved as a tumor suppressor in pancreatic cells,
which was contradictory with its proposed oncogenic prop-
erties described in the literature. To further confirm this
surprising result, both splice variants were overexpressed
in two additional pancreatic adenocarcinoma cell lines. As
observed for the two previous cell lines, colony formation
was induced by FGFR3 in both the Mia PaCa-2 and
PANC-1 cells, independently of FGFR3-IIIc kinase activity
for the PANC-1 cells (Table 1). However, this time, colony
size was unexpectedly significantly enhanced even when
the FGFR3-IIIc lacked kinase activity (Table 1). This
feature was in agreement with increased proliferation
(Figure 1D). In Mia Paca-2 cells, cell cycle analysis by
flow cytometry showed that cells in S phase were about
2-fold more numerous in the presence of FGFR3 forced
expression (Additional file 1: Figure S1). Senescence was
not detected in PANC-1 cells and was low but decreased in
Mia PaCa-2 cells (Table 1 and Additional file 2: Figure S2B).
In vivo tumor formation confirmed the in vitro data
since overexpression of both FGFR3-IIIb and –IIIc
strongly promoted PANC-1 (2-3-fold increase, Table 1)
and even more the Mia PaCa-2 (13-17-fold increase,
Table 1) tumor growth.
It seemed that FGFR3 impacted cancer cell clonogenic
properties independently of its kinase activity. We further
tested Capan-2 cell migration capacities. Again cell migra-
tion was increased by FGFR3, independently of its kinase
activity (Table 1).
The different responses of the cells could be linked to
various endogenous FGFR3 levels, before over-expression.
Western-blots showed that BxPC-3 cells expressed the
highest levels of the receptor, and the Mia PaCa-2 cells
the lowest (Figure 2A). The two other cell lines displayed
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Table 1 FGFR3 impact in pancreatic tumour cell lines
Epithelial-like Mesenchymal-like
Capan-2 BxPC-3 Mia PaCa-2 PANC-1
Colony
formation
(Ratio/CT)
Colony
area
(μm2)
Migration
(number
of cells)
Senescent
cells (%)
Tumour
mass
(mg)
Colony
formation
(Ratio/CT)
Colony
area
(mm2)
Tumour
mass
(mg)
Colony
formation
(Ratio/CT)
Colony
area
(mm2)
Migration
(number
of cells)
Senescent
cells (%)
Tumour
mass
(mg)
Colony
formation
(Ratio/CT)
Colony
area
(mm2)
Tumour
mass
(mg)
CTRL 1 ± 0.13 19.3 ± 5.0 997 ± 6 24.4 ± 5.3 203 ± 37 1 ± 0.18 24.2 ± 15.1 42 ± 0.01 1 ± 0.004 13.8 ± 4.7 98 ± 2 8.6 ± 1.9 21 ± 3 1 ± 0.05 9.9 ± 9.2 59 ± 39
FGFR3-IIIb 1.38 ± 0.06* 9.1 ± 1.5* 1524 ± 26*** 35.7 ± 3.9** 110 ± 12* 0.97 ± 0.10 15.9 ± 11.9** 25 ±0.01* 1.52 ± 0.18** 17.0 ± 4.6** 346 ± 9*** 4.7 ± 1.9*** 292 ± 133* 1.28 ± 0.04* 21.5 ± 14.1*** 137 ± 51*
FGFR3-IIIc 1.52 ± 0.27* 6.3 ± 1.5** 2050 ± 18*** 32.4 ± 5.5* 111 ± 14* 1.37 ± 0.04* 12.7 ± 9.7*** 23 ± 0.01* 1.28 ± 0.17* 23.7 ± 8.1*** 515 ± 22*** 5.0 ± 1*** 367 ± 113** 1.23 ± 0.04* 22.8 ± 14.6*** 138 ± 39*
FGFR3-IIIc-KD 1.21 ± 0.05* 15.7 ± 11.1 1492 ± 10*** 16.9 ± 3.26* 212 ± 71 1.26 ± 0.04** 20.9 ± 14.2 ND ND ND ND ND ND 1.55 ± 0.12* 15.1 ± 8.7** ND
Cells were transduced to obtain 70% of transduced cells as analyzed by flow cytometry. For colony formation assays, 500 cells were plated in 10 mm dished in triplicates. Dishes were processed for violet crystal
staining and blind counted. Colony areas were measured with Image J software. Senescence was detected as indicated in the methods section. Senescence was not detectable in BxPC-3 and PANC-1 cells. Results are
reported as means ± SD except for tumour masses ± SEM. *: p < 0.05 **: p < 0.01 ***: p < 0.001 as compared to control. Ratio/CT: results are expressed as ratio over the control condition. ND: not done.
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Figure 1 FGFR3 has tumor suppressor gene properties in BxPC-3 and Capan-2 pancreatic cell lines. A) Capan-2 cells were transduced with
either control (a,d), FGFR3-IIIb (b,e) or FGFR3-IIIc ZsGreen lentivectors (c,f) and observed with a fluorescence microscope (original magnification ×40,
bright field, a,b,c, green fluorescence, d,e,). Colonies with strong overexpression of either FGFR3-IIIb or –IIIc were smaller (arrows heads, b, c, e, f) than
colonies with lower expression (arrows). Right panel: mean fluorescence intensity was determined for colonies transduced with the same lentivectors
as in left panel, and were also transduced with a lentivector carrying a FGFR3-IIIc cDNA with the K508M mutation inactivating the kinase domain.
B) FGFR3-IIIb and –IIIc overexpression decreased Capan-2 and BxPC-3 cell proliferation and (C) increased apoptosis. (D) FGFR3 forced expression had
opposite effect on cell proliferation of Mia PaCa-2 and PANC-1 cells. NS: nor significant, *p = 0.05, **p < 0.01, ***p < 0.001.
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similar intermediate FGFR3 protein levels, but opposite
behavior in response to FGFR3 forced expression. RT-
qPCRs further showed that FGFR3-IIIb isoform was more
abundant, except for the Mia PaCa-2 cells (Figure 2B). In
addition total FGFR3 was detected by immunofluores-
cence in the cell lines, and we noticed that it had nuclear
localization in PANC-1 and MiaPaCa-2 cells, but not in
Capan-2 or BxPC-3 cells (Additional file 4: Figure S4).
In Normal Human Keratinocytes (NHEK), signal was
detected throughout the whole cells. Thus total FGFR3
levels or distinct FGFR3 splice variant relative abundance
could not explain the opposite phenotypes.
FGFR-IIIb isoform is preferentially expressed in cells
of epithelial origin and FGFR-IIIc isoforms in mesenchymal
cells [14]. RT-qPCRs were performed to assess the levels
of expression of E-cadherin and vimentin, markers of epi-
thelial and mesenchymal cells, respectively (Figure 2C).
Capan-2 and BxPC-3 cells displayed epithelial charac-
teristics (strong E-cadherin expression, almost no vimentin
expression). The Mia PaCa-2 line was mesenchymal-like
(no E-cadherin expression and strong vimentin expression)
and PANC-1 s displayed an intermediate phenotype since
they still expressed some E-cadherin but did express high
levels of vimentin. These cells retained characteristics of
epithelial cells in terms of cell shape, like the Capan-2
and BxPC-3 cells, while the Mia PaCa-2 cells resembled
fibroblasts (Figure 2D). Thus, our experimental cell models
were distinguishable in three categories: the epithelial-like
cells (BxPC-3 and Capan-2), the mesenchymal-like cells
(Mia PaCa-2) and cells with intermediate phenotype
(PANC-1).
In light of this data, it appeared that in epithelial-like
pancreatic cells (BxPC-3 and Capan-2), FGFR3 had tumor
suppressive effects, while in cells with mesenchymal cell
features (Mia PaCa-2 and PANC-1), FGFR3 had oncogenic
effects.
To further explore the impact of FGFR3 in epithelial
cells, the proliferation of the mouse pancreatic epithelial
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Figure 2 Phenotypic properties of PDAC cell lines. A) FGFR3 expression in the PDAC cell lines was determined by western-blot. FGFR3
expression was the highest in BxPC-3 cells and the lowest in Mia PaCa-2 cells. Membranes were reprobed for GAPDH to test equivalent loading.
B) FGFR3 splice variants relative mRNA level were determined by RT-qPCR with specific primers and normalized with RPLP0 used as a mRNA
expression internal reference. C) Epithelial E-cadherin and mesenchymal vimentin markers mRNA levels were determined by RT-qPCR. Capan-2
and BxPC-3 cells were epithelial, whereas the Mia PaCa-2 cell line was more mesenchymal. PANC-1 cells displayed an intermediate phenotype.
D) Light microscope pictures of the four tested cell lines (original magnification ×40). PANC-1 presented an epithelial phenotype despite the
strong expression of vimentin.
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beta cell line BTC [15] was assessed in the presence of a
neutralizing anti-FGFR3 antibody or with FGFR3-IIIc
splice overexpression in vitro. The inhibition of FGFR3
activity increased BTC cell proliferation, while transient
forced expression of FGFR3-IIIc significantly diminished
BTC cell expansion (Figure 3A). When BTC cells over-
expressing FGFR3-IIIc were xenografted in immune de-
ficient mice, tumor progression was strongly inhibited as
compared to control cells (Figure 3B and Additional file
5: Figure S5). This suggests that as in pancreatic adeno-
carcinoma cell lines with epithelial phenotype, FGFR3
limits beta cell growth.
FGFR3 ligands are differentially expressed in pancreatic
cell lines
The different responses of the cell lines to FGFR3 signal
could be related to distinct status in available FGFs. We
performed all the in vitro experiments in complete media,
without modulating the levels of FGFs. The reason was
that all the PDAC cell lines expressed endogenous FGFs
that could bind either splice variants of the receptor
(Additional file 6: Figure S6A). Indeed, RT-qPCR aimed
to evaluate the relative levels of known ligands for
FGFR3 in the parental cells showed that FGF4 and
FGF23 were not detectable. CAPAN2 cells expressed
FGF17 and FGF18, also present in the MIAPACA2 cells
at similar levels. Interestingly however, distinct profiles
were obtained for other FGFs. Strikingly, MIAPACA2 and
PANC1 cells expressed very high levels of FGF2 mRNAs,
which were almost not detectable in the epithelial-like cells.
Moreover, the CAPAN2 cells expressed FGF9, which was
also detected at a lower level in BXPC3s, but not the two
other cell lines. Importantly, FGF2 and FGF9 levels were
increased in cells overexpressing FGFR3 (Additional file 6:
Figure S6B), suggesting that autocrine loops in parental cell
lines are reinforced with FGFR3 forced expression.
Thus it seems that distinct autocrine loops are present
in the PDAC cell lines for FGFR3. FGF2 was clearly
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Figure 3 FGFR3 conveys a negative signal in the pancreatic beta cell line BTC. A) BTC cells were cultured in the absence (CT) or in the
presence of the neutralizing anti-FGFR3. Alternatively, cells were transiently transfected with a vector overexpressing FGFR3-IIIc or a control vector
(CT). B) Tumors were produced from parental BTC cells (n = 12) or clones of BTC cells overexpressing stably FGFR3-IIIc (n = 17). Tumor masses
were determined 6 weeks after cells were injected. ***: p < 0.001, **: p < 0.01.
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associated with the MIAPACA2 and the PANC1 cells,
but not cells with an epithelial phenotype.
FGFR3 signaling is different in pancreatic epithelial and
mesenchymal-like cells
In the presence of the ligand, the dimerization of the
receptor triggers FGFR transphosphorylations, to create
docking sites for downstream signaling factors activating
pathways such as RAS and the downstream MAP Kinases,
the PI3Kinase/Akt pathway or the Signal transducer and
activator of Transcription (STAT) pathway. The protein
extracts of tumors overexpressing FGFR3 with the strongest
and opposite phenotypes (Capan-2 and Mia PaCa-2 cells)
were analyzed by western-blotting. Active JNKs, detectable
only in Capan-2 cells, were unchanged (not shown). In
FGFR3-Capan-2 cells, other activated MAP Kinases
were unchanged (Figure 4), but in Mia PaCa-2 cells both
ERKs and P38 were over-activated (Figure 4). Conversely,
phosphorylation of STATs was found strongly increased
by FGFR3 overexpression in Capan-2 cells but was not
detected in Mia PaCa-2 cells. This effect in Capan-2 cells
disappeared when transduced with FGFR3-IIIc-KD.
Although AKT was present in all the tumor extracts,
no changes were observed in activated AKT (not shown).
The proteins p21 and p27, downstream effectors of FGFR3
in chondrocytes [2] were mildly increased in FGFR3-
Capan-2 tumors (Figure 3), but not in the Mia PaCa-2
(not detectable). Since apoptosis was found up-regulated
in FGFR3-Capan-2 cells, we looked at apoptosis markers.
BAX signal was stronger in FGFR3 conditions, while
BCL2 remained unchanged (Figure 4). Thus the bal-
ance of anti-apoptotic/pro-apoptotic proteins was moved
towards apoptosis. This was further confirmed by in-
creased levels of both cleaved caspase 9 and caspase 3
(Figure 4). In Mia PaCa-2 s, there was no obvious
change in the anti-apoptotic/pro-apoptotic balance
and cleaved caspases were not detectable (Figure 4).
Senescence often depends on p53 activation or stabilization.
The Capan-2 cells were the only cell line in our hands
bearing wild type copies of TP53. Total p53 and
MAPKs
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Figure 4 FGFR3 engaged diverse intracellular pathways. Proteins extracts of tumors from Capan-2 and Mia PaCa-2, were analyzed by
western-blot. See text for more details. CKIs: Cyclin-dependant kinase inhibitors. Membranes were reprobed for GAPDH to test equivalent loading.
Results shown are representative of one out of at least 3 independent experiments.
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Phospho-p53 were not changed in FGFR3 overexpressing
cells (not shown).
Finally, autophagy can promote proliferation or apop-
tosis. LC3B protein conversion status was evaluated. Both
LC3B-I and LC3B-II peptides were detected, indicating
that autophagy is active in Capan-2 cells. However, FGFR3
did not induce any change in LC3B-I cleavage (band inten-
sity of LC3B-II/LC3B-I, Figure 4B). In Mia PaCa-2 cells,
the basal levels of both LC3B forms were increased in the
presence of FGFR3 overexpression, together with the rate
of LC3B-I cleavage (Figure 4). This suggests that FGFR3
promoted autophagy in the Mia PaCa-2 cells.
Thus, it seemed that in epithelial-like cells FGFR3
activated STATs but not ERKs and in mesenchymal
cells, it was the opposite. To further explore this point,
western-blots were performed with tumor extracts from
BxPC-3 and PANC-1 cells. As in Capan-2 cells, BxPC-3
cells showed increased STATs activation and unchanged
P-ERK levels (Additional file 7: Figure S7). Surprisingly, in
PANC-1, none of the tested signaling seemed affected by
FGFR3 forced expression, despite phenotypes similar to
what was observed in the MiaPaCa-2 cells (Additional file
7: Figure S7). P-ERKs and P-JNKs were evidenced but not
modulated and P-p38 was undetectable even if p38 was
present (Additional file 7: Figure S7). In the same way
although P-STAT1 proteins were detected in the PANC-1
cell extracts, they were not induced by either FGFR3 splice
variant. BAX and Bcl-2 were unchanged. Thus, in PANC-1
cells, the oncogenic effect of FGFR3 was evidenced, but it
clearly depended on intracellular signals different from
those in the Capan-2 or the MiaPaCa-2 cells. Cell prolifer-
ation capacities are strongly modulated by phosphoryl-
ation of RB1 protein. This protein is detected and active
in many PDAC cell lines, including the ones used in the
present report [16]. RB1 phosphorylation at serine 795
was induced in PANC1 cells overexpressing FGFR3
but not in Capan-2 cells where it was detectable or
MIAPACA2 cells where it was undetectable, suggesting
that RB1 activity was diminished in PANC1 cells (Additional
file 7: Figure S7). In the same way, CREB phosphorylation
was induced in PANC1 cells and was undetectable in
CAPAN2 cells or in MIAPACA2 cells.
Thus, FGFR3 intracellular partners were the same
in the epithelial-like cancer cells, but different in the
mesenchymal-like cells.
FGFR3 expression is downregulated in human pancreatic
tumor tissues
To gain insight into the impact of FGFR3 signalling path-
way specifically in pancreatic cancers, pancreatic cancer
tissues were analyzed for the levels of expression of the
receptor compared to normal pancreatic tissue.
Strong FGFR3 immune signal was found in normal
pancreatic islets, while a weak signal was present in the
exocrine tissue (Figure 5a,b). FGFR3 was co-localized
with insulin-positive cells, but was also present in non
beta cells in islets (Figure 5c). Both splice variants
appeared to be equally abundant in the normal pancreas
(Additional file 8: Table S1).
In cancer tissues, we found a significant decrease of
FGFR3 RNAs in PDAC as compared to normal pancreas,
regardless of the splice variant, which balance did not
change (Additional file 8: Table S1). In tissue microarrays,
when compared to FGFR3 signal intensity in normal
pancreas (high in islets, weak in ducts), about 70% of
the pancreatic endocrine carcinomas showed partial or
total loss of FGFR3 signal (Figure 5d-f ). 63% of the
intraductal papillary mucinous neoplasms and 30% of
the pancreatic ductal adenocarcinomas showed total
loss of FGFR3 signal. Some of the two latter cancer tissues
displayed areas with strong staining, but it was always
highly heterogeneous (Figure 5g-l), some regions totally
lacking FGFR3, on the same sections (Figure 5i and 5l).
Thus, FGFR3 transcripts and protein seemed to be lost
in a non negligible proportion of pancreatic tumors,
especially in endocrine tumors.
Discussion
The impact of FGFR3 mutations in various tumors can be
revisited in light of the present study
Early published data converged towards oncogenic
properties of FGFR3. Indeed, in multiple myelomas, the
chromosomal translocation t(4;14)(p16.3;q32) results in
ectopic overexpression of FGFR3 [12]. Further, FGFR3 was
considered as an oncogene in hematopoietic cell models
[17] and in 3T3 fibroblast, but not in the T24 epithelial
cells [18]. In other soft tissue tumors such as synovial
carcinomas or rhabdomyosarcomas, FGFR3 was involved
in the malignant phenotype [19,20]. Results in Mia PaCa-2
cells (this work) and SW480 [11] support the notion that
in tumors originating from mesenchymal cells, FGFR3 is
an oncogene.
However, puzzling observations were previously un-
explained and even incompatible with FGFR3 being an
oncogene. First, the receptor has a negative regulatory
role during bone development. In colorectal cancers, a
group noticed frequent inactivation of the receptor or
downregulation of the protein [10]. Importantly, frequent
loss of heterozygosity of the chromosomal region carrying
FGFR3 gene (the 4p16.3 locus) has been characterized,
suggesting that this region carries a tumor suppressor
gene [21]. In that context, it was surprising to find FGFR3
as an oncogene in this locus. FGFR3 expression was re-
duced in almost 60% of cervix tumors and when it was in-
creased, it was in tumors of good prognosis [22]. Later on,
critical data showed a significant association of loss of
FGFR3 and tumor stage in high grade urothelial bladder
cancers [23]. Accordingly, FGFR3 activating mutations were
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associated with early, non invasive, low grade papillary tu-
mors and never found in carcinomas in situ [24]. Conse-
quently, active mutants of FGFR3 are now associated with
low grade tumors in urothelial cancers and possible loss of
heterozygosis at FGFR3 locus might accompany the
switch to higher grades (reviewed in [25]). In the same
way, in seborrheic keratoses and epidermal nevi, benign
tumors of the skin very rarely progressing into malignant
disease, also present high rates of activating mutations of
FGFR3 (reviewed in [9]), suggesting a protective role of
increased FGFR3 in these models, of epithelial origin. Our
data support the concept that FGFR3 signal in epithelial
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Total loss
Total loss
Partial loss Normal level
Normal level
Normal level
Heterogeneity
Heterogeneity
Signal intensity IPMN PEC PDAC
Negative 63.3% (19) 12% (3) 30.6% (27)
Weakly positive 30%  (9) 56% (14) 48.9% (43)
Strongly positive 6.7%( 2) 32% (8) 20.5 (18)
Total number of tumors 30 25 88
A
B
Figure 5 FGFR3 expression in normal and pancreatic tumor tissues. A: (a, b) FGFR3 signal was found in islets of normal pancreas.
(c) Co-localization of FGFR3 (green) and insulin (red). Nuclei were stained with DAPI (blue). (d-l) FGFR3 expression was assessed according to the
signal obtained in normal pancreas (strong in islets, weak in the exocrine tissue). Twelve percent of pancreatic endocrine carcinomas (PEC, n = 25)
displayed no FGFR3 signal (d), 56% showed weak (e) and only 32% had strong (normal, f) FGFR3 expression. For Intraductal papillary mucinous
neoplasms (IPMN, n = 30), 63.3% had no signal (g), 30% had weak signal (normal, h) and 6.7% showed strong (i) FGFR3 expression. In Pancreatic
ductal adenocarcinomas (PDAC, n = 88), 30.6% displayed no FGFR3 signal (j), 48.9% had weak (normal, k) and 20.5% showed strong (l) FGFR3
expression. Bars represent 50 μm. B: Table recapitulating the scoring of pancreatic tumors for FGFR3 signal. Strong signals were as intense as
signals obtained in normal pancreatic islets (A: a, b). Weak signals were similar to what was observed in normal pancreatic exocrine tissue
(ducts and acinar cells, A: a, b).
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context might actively participate to limit loss of prolifera-
tion control, and inhibit the switch to malignant disease.
In pancreatic cancer, this hypothesis is in agreement with
the loss of expression found in RNA and tissue sections
of pancreatic cancers (the present work). It would be
very interesting to check the status of cell phenotypes in
the same tumors to determine the proportion of lesions
which have undergone the epithelial to mesenchymal
transition. We did not have the clinical parameters of
the patients from whom the lesions came from. Additional
experiments are needed to determine whether loss of
FGFR3 signal correlates with bad prognosis of the disease.
Moreover, it would be interesting to test the possibility
that pancreatic lesions with mesenchymal phenotype
retain FGFR3 expression. In colorectal cancer models
[11], authors could not explain the loss of FGFR3 expression
in human tumors since they believed that FGFR3 was an
oncogene. However, they found, like us, a downregulation
of FGFR3 expression in colorectal cancers. They used
several colorectal cancer cell lines to evaluate FGFR3
impact on growth and migration. They could not obtain
FGFR3 transfectants with the CaCo2 cell line and observed
the HCT116 cells being inhibited by FGFR3 overexpression.
Opposite phenotype was reported in the SW480 cells, and
the main conclusions of the report were drawn based on
this cell line only. Interestingly, HCT116 cells express high
levels of E-cadherin and low levels of vimentin [26], while
SW480 cells do not express E-Cadherin [27], but vimentin
[28]. It is possible that CaCo2 cells died in the presence
of FGFR3 forced expression. We ourselves encountered
difficulties in obtaining single Capan-2 or BTC clones
with FGFR3-IIIc overexpression. Thus the conclusions
of Sonvilla et al. might be reformulated in light of our
results.
Molecular mechanisms of FGFR3 signals in PDAC cells
FGFR3 oncogenic effect seemed to be conveyed by MAP
kinases activation in the Mia PaCa-2 cells, even if several
studies report that KRAS is mutated in that cell line, as in
most PDAC cells. It means that an alternative pathway
transmitted FGFR3 signal in those cells to over-activate
MAP kinases. This activation but not that of STATs is
similar to what was found in multiple myelomas [29]. The
differences in percentages found in flow cytometry analyses
could not explain the differences in cell counts. It is pos-
sible that the higher rate of autophagy contributes to cell
growth promotion in these cells, as suggested by variations
in LC3B levels and cleavage rate. This hypothesis needs
further analysis in future. Interestingly, in PANC-1 cells
FGFR3 had oncogenic properties but signaling was differ-
ent to what was evidenced in Mia PaCa-2s. Alternative
pathways might occur depending on intracellular available
adaptors and lead to phenotypes with different intensities
as observed in this study.
Distinct autocrine loops were evidenced in PDAC cells.
It is possible that opposite effects were FGF-dependent
(FGF2 for the oncogenic effect and FGF9 for the tumor
suppressive effect), the role of FGF2 being supported by
previous studies ([30] for example) but more work is
needed to test the dependency of FGFR3 to FGFs.
The most relevant finding of this study is the tumor
suppressive properties of FGFR3 in pancreatic ductal
adenocarcinoma epithelial cells. In the growth plates of
developing long bones, FGFR3 negatively controls cell
proliferation and induces chondrocyte apoptosis in late
embryonic stages, noticeably through STATs activation
(reviewed in [2]). This, together with induction of senes-
cence could account for the loss of cell numbers observed
in our proliferation assays. It has been shown recently that
FGFR3-IIIc can induce premature reversible senescence in
chondrocytes [31]. Authors found, like us, that p53 was
active in their cells but that FGFR3-induced senescence
was independent of p53. In our hands, the main difference
between the epithelial-like and the mesenchymal-like cell
response to FGFR3 signal was the activation of STATs,
which can elicit senescence response independent of p53
[32]. Since we found p21 modestly induced in FGFR3
overexpressing cells, it is possible that activated STATs
directly controlled CDKN1A gene promoter, as earlier
described [33].
The present data raise the possibility that FGFR3 has
biphasic effects during multistage carcinogenesis in
carcinomas, acting first as a tumor suppressor through
oncogene-induced senescence via STATs activation and
apoptosis enhancement. In this context, FGFR3 loss would
help tumor progression. Alternatively, after additional
mutations have occurred in the developing tumor, decoup-
ling FGFR3 from its canonical inhibitory pathway (STATs),
FGFR3 signal might be redirected to other intracellular
factors, promoting tumor progression (Figure 6). In the
same way, epithelial to mesenchymal phenotype transition
would reveal FGFR3 as an oncogene by coupling the
receptor to MAP kinases pathways. This model supports a
new aspect of FGFR3 function, explaining why in epithe-
lial cancers FGFR3 activating mutations were associated
with good prognosis tumors whereas in soft tissue cancers,
FGFR3 promoted tumor progression. More importantly,
this work might open a new debate on the use of FGFR3
inhibitors in anticancer therapy.
Materials and methods
Animals, pancreatic cell lines and antibodies, tissue
specimens
The 6 to 8 week-old NOD/Shi-SCID IL2Rγnull mice were
produced and housed at the University Bordeaux Segalen
animal facility A2, according to the rules and regulations
of the Institutional Animal Care and Use Committee
(agreement number A33063916).
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The BxPC-3 and Capan-2 cells were provided by Joel
Tardive-Lacombe (INSERM U624, Marseille, France).
The cells were maintained in RPMI (Invitrogen, Saint
Aubin, France) with 10% Fetal Calf Serum (FCS, Invitrogen)
with Penicillin/Streptomycin 1/100 (Invitrogen). Mia
PaCa-2 and PANC-1 cells were purchased from the
ATCC (Teddington, United Kingdom) and maintained in
DMEM with 10% FCS and 1/100 Penicillin/Streptomycin
(Invitrogen). The BTC cells were obtained from Simon
Efrat (Tel Aviv University, Israel).
The following antibodies were used: FGFR3 (SIGMA-
ALDRICH, Lyon, France), Phospho-p44/p42 MAPK, p44/
p42 MAPK, Phospho SAPK/JNK, SAPK/JNK, Phospho
Akt, Akt, Caspase-3, Caspase-9, Phospho-STAT1, Phospho-
STAT3, BAX, p21, p27, Phospho-p38, p38, GAPDH
(all from Cell Signaling, Saint-Quentin en Yvelines, France).
Tissue specimens were obtained with informed consent
from all patients. Tissue arrays were stained with anti-
FGFR3 antibody using the Duolink® system (Eurogentec,
Angers, France) with which primary antibody detection
depends on a very specific PCR system, giving a punctuated
brown signal.
Vector construction and transduction of cells
The pMND-IRES2-ZsGreen1 was used as recipient vector
of all the constructs. FGFR3-IIIb and FGFR3-IIIc and
FGFR3-IIIIc-K508M were kindly provided by David
Cappellen (EA2406, Univ. Bordeaux, France) and Pavel
Krejci (Medical Genetics Institute, Los Angeles, California),
respectively and cloned upstream the IRES sequence.
FGFR3-IIIb and FGFR3-IIIc overexpressing cell lines
were obtained by transduction of lentiviral plasmids.
Control cells were produced by transduction of the empty
pMND-IRES-ZsGreen vector. For xenografts, transduced
cells were sorted by a BD FACS ARIA cell sorter (BD
Biosciences, Le Pont de Claix, France).
Isolation of RNA, cDNA synthesis, and quantitative
real-time PCR analysis
Total RNA was isolated using Trizol® and treated by DNAse
according to the manufacturer’s instructions (Invitrogen
and Ambion, Saint Aubin, France). cDNAs were synthesized
using Reverse transcriptase cDNA synthesis kit (Roche
Applied Science, Meylan, France). Quantitative real-time
PCR assays were performed with the SYBR® Green Master
Mix and carried out on a Stratagene MX-3005P system
(Stratagene, Massy, France). Sequences of primers can be
provided upon request.
Protein extraction and western-blotting
Protein extracts and western blotting were performed as
already described [34].
Cell cycle analysis
Non synchronized subconfluent cells were harvested and
washed twice with PBS then fixed with 70% ethanol in
PBS overnight at 4°C. Cells were washed twice with PBS
and incubated with a mix containing RNAse (1 mg/ml,
SIGMA-ALDRICH) and PBS-Propidium iodide (0.5 μg/ml,
SIGMA-ALRICH) for 15 min. The samples were examined
on a BD FACS CANTO II apparatus and the data were
analyzed with BD FACSDiva software (BD Biosciences,
Le Pont de Claix, France).
SA-β-Galactosidase labeling
SA-β-galactosidase activity was observed with an inverted
Nikon Microscope (Eclipse Ti Nikon, Champigny sur Marne,
France). Pictures were taken with the NIS-Elements
Nikon software. For SA-β-galactosidase positive cell quan-
tification, cells were counted on twenty separate fields and
the means of (100*number of blue cells/number of total
cells) were calculated corresponding to the percent of
SA-β-galactosidase positive cells. The numbers of counted
cells were for the Capan-2: CTRL (1914), FGFR3-IIIb
Figure 6 FGFR3 actions in pancreatic cancers: a working model. FGFR3 action in cancer cells from epithelial origin limits tumor growth.
During tumor progression, FGFR3 disruption or loss of expression promotes cell growth. If epithelial to mesenchymal transition occurs, then
FGFR3 will function as an oncogene favoring tumor progression.
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(2809), FGFR3-IIIc (3159), FGFR3-IIIc-KD (1687); For the
MIAPAC2: CTRL (2345), FGFR3-IIIB (2718), FGFR3-IIIc
(2563).
Xenografts of PDAC cell lines
Groups of at least 5 mice were anesthetized with isoflurane.
8×105 cells (4×105 for BTC cells) in 100 μl serum-free
medium were injected in the right flanks. When tumors
were visible, measures with a calibrator were done 3 times
a week. Tumors were resected and weighed at various
times after the initial grafts, according to the cell line.
Statistical analysis
In vitro results are expressed as mean ± SD. Results in vivo
are expressed as mean ± SEM. Statistical tests were
performed with unpaired, bilateral Student’s t tests.
Additional files
Additional file 1: Figure S1. Flow cytometry analyses of pancreatic cell
lines overexpressing FGFR3s. A: Capan-2 cells, B: BxPC-3 cells,
C: MiaPaCa-2 cells.
Additional file 2: Figure S2. SA-β-Galactosidase staining is associated
with senescent cell phenotype. The staining was conducted on CAPAN2
(a, b, c) and MIAPACA2 (d, e, f) cells expressing either control, FGFR3-IIIb
or –IIIc lentivectors. Senescent cells were counted in CAPAN2 cells (A, IIIb
p = 0.002**; IIIc p = 0.02*) and in MIAPACA2 cells (B, IIIb p = 0.0002***;
IIIc p < 10 -5 ***). Black arrows: blue senescent cells.
Additional file 3: Figure S3. FGFR3-IIIc tumor growth inhibition is
dependent on FGFR3-IIIc expression levels. Single clones overexpressing
FGFR3-IIIc in CAPAN-2 cells were xenografted in immuno-compromised
mice. Tumors were resected and FGFR3-IIIc-overexpression level was
determined by western-blot analysis of tumor-protein extracts for each
clones. FGFR3-IIIc level expression of each clone was finally compared to
the tumor mass. The regression was performed in Excel software.
Additional file 4: Figure S4. FGFR3 immuno-detection in pancreatic
pareantal cell lines. Parental cell lines were culture on LABTEK chambers
and FGFR3 presence was detected by immunofluorescence. Normal
Human Epithelial Keratinocytes (NHEK) were used as positive controls for
FGFR3 presence. Original magnification ×400.
Additional file 5: Figure S5. Western-blot of BTC cell extracts. Protein
extracts from parental BTC line (lane 1) or from clones with FGFR3
overexpression (lane 2–7) have been subjected to western-blotting to
detect FGFR3 and P-ERKs proteins levels. Actin protein was used as a
loading control.
Additional file 6: Figure S6. FGF expression in pancreatic cancer cell
lines. A) RT-qPCRs were performed as indicated in the materials and
methods section to measure the levels of expression of different FGFR3
ligands in the parental cell lines. Primers sequences can be provided
upon request. B) RT-qPCRs for FGF2 and FGF9 transcripts were performed
on RNA extracts from cells transduced with FGFR3-IIIb and –IIIc variants
or parental cells (CTRL). Results are reported according to the levels
fround in CTRL. *: p < 0.05, **: p < 0.01, ***: p < 0.001 (n = 3, as compared
to CTRL levels). Note that FGF9 was not detectable in MiaPaCa-2.
Additional file 7: Figure S7. Signaling pathways in BxPC-3 and PANC-1
tumor extracts. Proteins extracts of tumors from BxPc-3 and Mia PaCa-2,
were analyzed by western-blot. See text for more details. CKIs: Cyclin-
dependant kinase inhibitors. Membranes were reprobed for GAPDH to
test equivalent loading. Results shown are representative of one out of at
least 3 independent experiments.
Additional file 8: Table S1. FGFR3 mRNA expression in normal pancreas
and PDAC.
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